logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5598.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5598.produseast1
Journal Article
|Review

Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis

Seddon JA, Achar J, Malik AA, Hughes J, Burzynski J, Chen C, Denholm JT, Dravniece G, Fox GJ, Furin J, Geliukh E, Goncharova O, Guglielmetti L, Harries AD, Hesseling AC, Nguyen BH, Kavenga F, Khan U, Kherabi Y, Kiria N, Kock Y, Liu Q, Mesic A, Moore DAJ, Mubanga A, Naidoo L, Nilsen D, Piubello A, Reuter A, Rich ML, Satyanarayana S, Schaaf HS, Schoeman I, Skrahina A, Udwadia Z, Khan PY, Esmail H, Martinez L

Similar Content
Loading...
Loading...
Loading...
Summary Points

Individuals exposed to a person with infectious multidrug-resistant or rifampicin-resistant (MDR-RR) tuberculosis are at risk of developing tuberculosis disease. Historically, insufficient empirical evidence for preventive treatment in this group has permitted inadequate guidance for clinical decision making. However, several high-quality studies have been published detailing preventive treatment options for these contacts at high risk. In this Review, we discuss the management of individuals exposed to patients with infectious MDR-RR tuberculosis. We pay particular attention to the entire spectrum of clinical care for this population, including baseline assessment, possible preventive treatments, follow-up, and shared decision making. We discuss the available evidence, the rationales for different management strategies, and the interactions with (and implications of) secondary comorbidities such as HIV or malnutrition.

Subject Area

antibiotic resistancetuberculosisdisease surveillance

Languages

English
DOI
10.1016/S1473-3099(25)00157-4
Published Date
06 Jun 2025
PubMed ID
41036784
Journal
Lancet Infectious Diseases
Dimensions Badge
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis | Journal Article / Review | MSF Science Portal